论文部分内容阅读
目的观察替米沙坦对2型糖尿病患者微量白蛋白尿(MAU)及肾功能的影响。方法将2型糖尿病伴有MAU的患者60例随机分为治疗组与对照组各30例。2组患者均给予糖尿病常规治疗,FBG控制在≤7.0mmol/L。治疗组在常规降糖治疗的基础上,加用替米沙坦治疗。比较2组治疗前后MAU、Scr、BUN等指标。结果2组治疗后MAU均低于治疗前,且治疗组低于对照组,差异均有统计学意义(P<0.05)。2组治疗前后BUN及Scr比较差异均无统计学意义(P>0.05)。结论在常规降糖治疗2型糖尿病的基础上加用替米沙坦降低MAU的作用更明显,值得推广。
Objective To observe the effect of telmisartan on microalbuminuria (MAU) and renal function in type 2 diabetic patients. Methods Sixty patients with type 2 diabetes mellitus and MAU were randomly divided into treatment group (n = 30) and control group (n = 30). Patients in both groups were given routine treatment of diabetes, FBG control in ≤ 7.0mmol / L. Treatment group on the basis of conventional hypoglycemic therapy, add telmisartan treatment. The MAU, Scr, BUN and other indexes before and after treatment were compared between the two groups. Results The MAU in both groups after treatment was lower than before treatment, and the treatment group was lower than the control group, the difference was statistically significant (P <0.05). There was no significant difference in BUN and Scr between the two groups before and after treatment (P> 0.05). Conclusions The effect of adding telmisartan to reduce MAU on the basis of conventional hypoglycemic treatment of type 2 diabetes is more obvious and worthy of promotion.